MicroRNA-222 and MicroRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer

Cancer

Volumn 119, Issue 24, 2013, Pages 4358-4365

  Lee, James C ^a,b   Zhao, Jing Ting ^a   Clifton Bligh, Roderick J ^a,b   Gill, Anthony ^b,c   Gundara, Justin S ^a,b   Ip, Julian C ^a,b   Glover, Anthony ^a,b   Sywak, Mark S ^b   Delbridge, Leigh W ^b   Robinson, Bruce G ^a,b   Sidhu, Stanley B ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Northern Translational Cancer Research Unit   (Australia)

Author keywords

circulating biomarkers; microRNA; papillary thyroid cancer; recurrence; tissue biomarkers

Indexed keywords

B RAF KINASE; MICRORNA; MICRORNA 1299; MICRORNA 146B; MICRORNA 155; MICRORNA 193B; MICRORNA 222; MICRORNA 620; MICRORNA 890; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GOITER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTINODULAR GOITER; PATIENT CODING; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENCE RISK; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TISSUE LEVEL; TISSUE MICROARRAY; VERY ELDERLY;

CIRCULATING BIOMARKERS; MICRORNA; PAPILLARY THYROID CANCER; RECURRENCE; TISSUE BIOMARKERS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 84889881151     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28254     Document Type: Article

References (39)

1. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009; 18: 784-791.
2. Liu S,. Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. Br J Cancer. 2001; 85: 1335-1339.
3. DeLellis RA, Lloyd R, Heitz P, Eng C, eds. Pathology and Genetics of Tumours of Endocrine Organs: World Health Organization Classification of Tumors. Lyon, France: IARC Press; 2004.
4. Leboulleux S, Rubino C, Baudin E,. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005; 90: 5723-5729.
5. Pacini F, Cetani F, Miccoli P, et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg. 1994; 18: 600-604.
6. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19: 1167-1214.
7. Lang BH-H, Lo C-Y, Chan W-F, Lam K-Y, Wan K-Y,. Staging systems for papillary thyroid carcinoma. Ann Surg. 2007; 245: 366-378.
8. Kim S-J, Lee KE, Myong JP, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2012; 36: 310-317.
9. Nam JK, Jung CK, Song BJ, et al. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg. 2012; 203: 436-441.
10. Cheng S, Serra S, Mercado M, Ezzat S, Asa SL,. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res. 2011; 17: 2385-2394.
11. Khoo MLC, Freeman JL, Witterick IJ, et al. Underexpression of p27/Kip in thyroid papillary microcarcinomas with gross metastatic disease. Arch Otolaryngol Head Neck Surg. 2002; 128: 253-257.
12. Kroh EM, Parkin RK, Mitchell PS, Tewari M,. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010; 50: 298-301.
13. Pallante P, Visone R, Croce CM, Fusco A,. Deregulation of microRNA expression in follicular cell-derived human thyroid carcinomas. Endocr Relat Cancer. 2010; 17: F91-F104.
14. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005; 102: 19075-19080.
15. Pallante P,. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 2006; 13: 497-508.
16. Tetzlaff MT, Liu A, Xu X, et al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol. 2007; 18: 163-173.
17. Zen K, Zhang C-Y,. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 2012; 32: 326-348.
18. Cookson VJ, Bentley MA, Hogan BV, et al. Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell Oncol (Dordr). 2012; 35: 301-308.
19. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ,. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010; 251: 499-505.
20. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011; 122: 11-19.
21. Bullock M, O'Neill C, Chou A, et al. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer. 2012; 19: 779-784.
22. O'Neill CJ, Bullock M, Chou A, et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 2010; 148: 1139-1145; discussion 1145-1146.
23. Lee JI, Jang HW, Kim SW, Kim J-W, Oh YL, Chung JH,. BRAFV600E mutation in fine-needle aspiration aspirates: association with poorer prognostic factors in larger papillary thyroid carcinomas. Head Neck. 2013; 35: 548-553.
24. Yoo EY, Shin JH, Ko EY, Han B-K,. Contribution of the BRAF mutation analysis in calcified thyroid nodules. AJR Am J Roentgenol. 2012; 198: 891-895.
25. Ambros V,. The functions of animal microRNAs. Nature. 2004; 431: 350-355.
26. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297.
27. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008; 26: 462-469.
28. Gao Y, Wang C, Shan Z, et al. miRNA expression in a human papillary thyroid carcinoma cell line varies with invasiveness. Endocr J. 2010; 57: 81-86.
29. Yip L, Kelly L, Shuai Y, et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 2011; 18: 2035-2041.
30. Zhang C, Kang C, Wang P, et al. MicroRNA-221 and -222 regulate radiation sensitivity by targeting the PTEN pathway. Int J Radiat Oncol Biol Phys. 2011; 80: 240-248.
31. Chou C-K, Chen R-F, Chou F-F, et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid. 2010; 20: 489-494.
32. Chou C-K, Yang KD, Chou F-F, et al. Prognostic implications of mir-146b expression and its functional role in papillary thyroid carcinoma [serial online]. J Clin Endocrinol Metab. 2013; 98: E196-E205.
33. Keutgen XM, Filicori F, Crowley MJ, et al. A panel of 4 miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin Cancer Res. 2012; 18: 2032-2038.
34. Mazeh H, Mizrahi I, Halle D, et al. Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid. 2011; 21: 111-118.
35. Vriens MR, Weng J, Suh I, et al. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer. Cancer. 2012; 118: 3426-3432.
36. Yuxia M, Zhennan T, Wei Z,. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol. 2012; 138: 2045-2050.
37. Bryant RJ, Pawlowski T, Catto JWF, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012; 106: 768-774.
38. Creemers EE, Tijsen AJ, Pinto YM,. Circulating MicroRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 2012; 110: 483-495.
39. Yu S, Liu Y, Wang J, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012; 97: 2084-2092.